Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial

Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a good functional outcome is not known. We investigated the safety a...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Lancet neurology Ročník 15; číslo 12; s. 1228 - 1237
Hlavní autoři:	Hanley, Daniel F, Thompson, Richard E, Muschelli, John, Rosenblum, Michael, McBee, Nichol, Lane, Karen, Bistran-Hall, Amanda J, Mayo, Steven W, Keyl, Penelope, Gandhi, Dheeraj, Morgan, Tim C, Ullman, Natalie, Mould, W Andrew, Carhuapoma, J Ricardo, Kase, Carlos, Ziai, Wendy, Thompson, Carol B, Yenokyan, Gayane, Huang, Emily, Broaddus, William C, Graham, R Scott, Aldrich, E Francois, Dodd, Robert, Wijman, Cristanne, Caron, Jean-Louis, Huang, Judy, Camarata, Paul, Mendelow, A David, Gregson, Barbara, Janis, Scott, Vespa, Paul, Martin, Neil, Awad, Issam, Zuccarello, Mario
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.11.2016 Elsevier Limited
Témata:	Aged Blood pressure Cerebral Hemorrhage - drug therapy Cerebral Hemorrhage - mortality Cerebral Hemorrhage - surgery Coma Combined Modality Therapy Female Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - adverse effects Fibrinolytic Agents - pharmacology Follow-Up Studies Hemorrhage Humans Intensive care Laparoscopy Male Middle Aged Minimally Invasive Surgical Procedures Mortality Neurology Outcome Assessment (Health Care) Patients Postoperative Hemorrhage - etiology Pragmatism Stroke Surgery Surgery, Computer-Assisted Thrombectomy - adverse effects Thrombectomy - methods Tissue Plasminogen Activator - administration & dosage Tissue Plasminogen Activator - adverse effects Tissue Plasminogen Activator - pharmacology
ISSN:	1474-4422, 1474-4465, 1474-4465
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a good functional outcome is not known. We investigated the safety and efficacy of alteplase, a recombinant tissue plasminogen activator, in combination with minimally invasive surgery (MIS) in patients with intracerebral haemorrhage. MISTIE was an open-label, phase 2 trial that was done in 26 hospitals in the USA, Canada, the UK, and Germany. We used a computer-generated allocation sequence with a block size of four to centrally randomise patients aged 18–80 years with a non-traumatic (spontaneous) intracerebral haemorrhage of 20 mL or higher to standard medical care or image-guided MIS plus alteplase (0·3 mg or 1·0 mg every 8 h for up to nine doses) to remove clots using surgical aspiration followed by alteplase clot irrigation. Primary outcomes were all safety outcomes: 30 day mortality, 7 day procedure-related mortality, 72 h symptomatic bleeding, and 30 day brain infections. This trial is registered with ClinicalTrials.gov, number NCT00224770. Between Feb 2, 2006, and April 8, 2013, 96 patients were randomly allocated and completed follow-up: 54 (56%) in the MIS plus alteplase group and 42 (44%) in the standard medical care group. The primary outcomes did not differ between the standard medical care and MIS plus alteplase groups: 30 day mortality (four [9·5%, 95% CI 2·7–22.6] vs eight [14·8%, 6·6–27·1], p=0·542), 7 day mortality (zero [0%, 0–8·4] vs one [1·9%, 0·1–9·9], p=0·562), symptomatic bleeding (one [2·4%, 0·1–12·6] vs five [9·3%, 3·1–20·3], p=0·226), and brain bacterial infections (one [2·4%, 0·1–12·6] vs zero [0%, 0–6·6], p=0·438). Asymptomatic haemorrhages were more common in the MIS plus alteplase group than in the standard medical care group (12 [22·2%; 95% CI 12·0–35·6] vs three [7·1%; 1·5–19·5]; p=0·051). MIS plus alteplase seems to be safe in patients with intracerebral haemorrhage, but increased asymptomatic bleeding is a major cautionary finding. These results, if replicable, could lead to the addition of surgical management as a therapeutic strategy for intracerebral haemorrhage. National Institute of Neurological Disorders and Stroke, Genentech, and Codman.
AbstractList	Summary Background Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a good functional outcome is not known. We investigated the safety and efficacy of alteplase, a recombinant tissue plasminogen activator, in combination with minimally invasive surgery (MIS) in patients with intracerebral haemorrhage. Methods MISTIE was an open-label, phase 2 trial that was done in 26 hospitals in the USA, Canada, the UK, and Germany. We used a computer-generated allocation sequence with a block size of four to centrally randomise patients aged 18–80 years with a non-traumatic (spontaneous) intracerebral haemorrhage of 20 mL or higher to standard medical care or image-guided MIS plus alteplase (0·3 mg or 1·0 mg every 8 h for up to nine doses) to remove clots using surgical aspiration followed by alteplase clot irrigation. Primary outcomes were all safety outcomes: 30 day mortality, 7 day procedure-related mortality, 72 h symptomatic bleeding, and 30 day brain infections. This trial is registered with ClinicalTrials.gov , number NCT00224770. Findings Between Feb 2, 2006, and April 8, 2013, 96 patients were randomly allocated and completed follow-up: 54 (56%) in the MIS plus alteplase group and 42 (44%) in the standard medical care group. The primary outcomes did not differ between the standard medical care and MIS plus alteplase groups: 30 day mortality (four [9·5%, 95% CI 2·7–22.6] vs eight [14·8%, 6·6–27·1], p=0·542), 7 day mortality (zero [0%, 0–8·4] vs one [1·9%, 0·1–9·9], p=0·562), symptomatic bleeding (one [2·4%, 0·1–12·6] vs five [9·3%, 3·1–20·3], p=0·226), and brain bacterial infections (one [2·4%, 0·1–12·6] vs zero [0%, 0–6·6], p=0·438). Asymptomatic haemorrhages were more common in the MIS plus alteplase group than in the standard medical care group (12 [22·2%; 95% CI 12·0–35·6] vs three [7·1%; 1·5–19·5]; p=0·051). Interpretation MIS plus alteplase seems to be safe in patients with intracerebral haemorrhage, but increased asymptomatic bleeding is a major cautionary finding. These results, if replicable, could lead to the addition of surgical management as a therapeutic strategy for intracerebral haemorrhage. Funding National Institute of Neurological Disorders and Stroke, Genentech, and Codman. Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a good functional outcome is not known. We investigated the safety and efficacy of alteplase, a recombinant tissue plasminogen activator, in combination with minimally invasive surgery (MIS) in patients with intracerebral haemorrhage. Methods MISTIE was an open-label, phase 2 trial that was done in 26 hospitals in the USA, Canada, the UK, and Germany. We used a computer-generated allocation sequence with a block size of four to centrally randomise patients aged 18-80 years with a non-traumatic (spontaneous) intracerebral haemorrhage of 20 mL or higher to standard medical care or image-guided MIS plus alteplase (0·3 mg or 1·0 mg every 8 h for up to nine doses) to remove clots using surgical aspiration followed by alteplase clot irrigation. Primary outcomes were all safety outcomes: 30 day mortality, 7 day procedure-related mortality, 72 h symptomatic bleeding, and 30 day brain infections. This trial is registered withClinicalTrials.gov, numberNCT00224770. Findings Between Feb 2, 2006, and April 8, 2013, 96 patients were randomly allocated and completed follow-up: 54 (56%) in the MIS plus alteplase group and 42 (44%) in the standard medical care group. The primary outcomes did not differ between the standard medical care and MIS plus alteplase groups: 30 day mortality (four [9·5%, 95% CI 2·7-22.6]vseight [14·8%, 6·6-27·1], p=0·542), 7 day mortality (zero [0%, 0-8·4]vsone [1·9%, 0·1-9·9], p=0·562), symptomatic bleeding (one [2·4%, 0·1-12·6]vsfive [9·3%, 3·1-20·3], p=0·226), and brain bacterial infections (one [2·4%, 0·1-12·6]vszero [0%, 0-6·6], p=0·438). Asymptomatic haemorrhages were more common in the MIS plus alteplase group than in the standard medical care group (12 [22·2%; 95% CI 12·0-35·6]vsthree [7·1%; 1·5-19·5]; p=0·051). Interpretation MIS plus alteplase seems to be safe in patients with intracerebral haemorrhage, but increased asymptomatic bleeding is a major cautionary finding. These results, if replicable, could lead to the addition of surgical management as a therapeutic strategy for intracerebral haemorrhage. Funding National Institute of Neurological Disorders and Stroke, Genentech, and Codman. Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a good functional outcome is not known. We investigated the safety and efficacy of alteplase, a recombinant tissue plasminogen activator, in combination with minimally invasive surgery (MIS) in patients with intracerebral haemorrhage. MISTIE was an open-label, phase 2 trial that was done in 26 hospitals in the USA, Canada, the UK, and Germany. We used a computer-generated allocation sequence with a block size of four to centrally randomise patients aged 18–80 years with a non-traumatic (spontaneous) intracerebral haemorrhage of 20 mL or higher to standard medical care or image-guided MIS plus alteplase (0·3 mg or 1·0 mg every 8 h for up to nine doses) to remove clots using surgical aspiration followed by alteplase clot irrigation. Primary outcomes were all safety outcomes: 30 day mortality, 7 day procedure-related mortality, 72 h symptomatic bleeding, and 30 day brain infections. This trial is registered with ClinicalTrials.gov, number NCT00224770. Between Feb 2, 2006, and April 8, 2013, 96 patients were randomly allocated and completed follow-up: 54 (56%) in the MIS plus alteplase group and 42 (44%) in the standard medical care group. The primary outcomes did not differ between the standard medical care and MIS plus alteplase groups: 30 day mortality (four [9·5%, 95% CI 2·7–22.6] vs eight [14·8%, 6·6–27·1], p=0·542), 7 day mortality (zero [0%, 0–8·4] vs one [1·9%, 0·1–9·9], p=0·562), symptomatic bleeding (one [2·4%, 0·1–12·6] vs five [9·3%, 3·1–20·3], p=0·226), and brain bacterial infections (one [2·4%, 0·1–12·6] vs zero [0%, 0–6·6], p=0·438). Asymptomatic haemorrhages were more common in the MIS plus alteplase group than in the standard medical care group (12 [22·2%; 95% CI 12·0–35·6] vs three [7·1%; 1·5–19·5]; p=0·051). MIS plus alteplase seems to be safe in patients with intracerebral haemorrhage, but increased asymptomatic bleeding is a major cautionary finding. These results, if replicable, could lead to the addition of surgical management as a therapeutic strategy for intracerebral haemorrhage. National Institute of Neurological Disorders and Stroke, Genentech, and Codman. Background Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a good functional outcome is not known. We investigated the safety and efficacy of alteplase, a recombinant tissue plasminogen activator, in combination with minimally invasive surgery (MIS) in patients with intracerebral haemorrhage. Methods MISTIE was an open-label, phase 2 trial that was done in 26 hospitals in the USA, Canada, the UK, and Germany. We used a computer-generated allocation sequence with a block size of four to centrally randomise patients aged 18-80 years with a non-traumatic (spontaneous) intracerebral haemorrhage of 20 mL or higher to standard medical care or image-guided MIS plus alteplase (0.3 mg or 1.0 mg every 8 h for up to nine doses) to remove clots using surgical aspiration followed by alteplase clot irrigation. Primary outcomes were all safety outcomes: 30 day mortality, 7 day procedure-related mortality, 72 h symptomatic bleeding, and 30 day brain infections. This trial is registered with ClinicalTrials.gov, number NCT00224770. Findings Between Feb 2, 2006, and April 8, 2013, 96 patients were randomly allocated and completed follow-up: 54 (56%) in the MIS plus alteplase group and 42 (44%) in the standard medical care group. The primary outcomes did not differ between the standard medical care and MIS plus alteplase groups: 30 day mortality (four [9.5%, 95% CI 2.7-22.6] vs eight [14.8%, 6.6-27.1], p=0.542), 7 day mortality (zero [0%, 0-8.4] vs one [1.9%, 0.1-9.9], p=0.562), symptomatic bleeding (one [2.4%, 0.1-12.6] vs five [9.3%, 3.1-20.3], p=0.226), and brain bacterial infections (one [2.4%, 0.1-12.6] vs zero [0%, 0-6.6], p=0.438). Asymptomatic haemorrhages were more common in the MIS plus alteplase group than in the standard medical care group (12 [22.2%; 95% CI 12.0-35.6] vs three [7.1%; 1.5-19.5]; p=0.051). Interpretation MIS plus alteplase seems to be safe in patients with intracerebral haemorrhage, but increased asymptomatic bleeding is a major cautionary finding. These results, if replicable, could lead to the addition of surgical management as a therapeutic strategy for intracerebral haemorrhage. Funding National Institute of Neurological Disorders and Stroke, Genentech, and Codman. Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a good functional outcome is not known. We investigated the safety and efficacy of alteplase, a recombinant tissue plasminogen activator, in combination with minimally invasive surgery (MIS) in patients with intracerebral haemorrhage.BACKGROUNDCraniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a good functional outcome is not known. We investigated the safety and efficacy of alteplase, a recombinant tissue plasminogen activator, in combination with minimally invasive surgery (MIS) in patients with intracerebral haemorrhage.MISTIE was an open-label, phase 2 trial that was done in 26 hospitals in the USA, Canada, the UK, and Germany. We used a computer-generated allocation sequence with a block size of four to centrally randomise patients aged 18-80 years with a non-traumatic (spontaneous) intracerebral haemorrhage of 20 mL or higher to standard medical care or image-guided MIS plus alteplase (0·3 mg or 1·0 mg every 8 h for up to nine doses) to remove clots using surgical aspiration followed by alteplase clot irrigation. Primary outcomes were all safety outcomes: 30 day mortality, 7 day procedure-related mortality, 72 h symptomatic bleeding, and 30 day brain infections. This trial is registered with ClinicalTrials.gov, number NCT00224770.METHODSMISTIE was an open-label, phase 2 trial that was done in 26 hospitals in the USA, Canada, the UK, and Germany. We used a computer-generated allocation sequence with a block size of four to centrally randomise patients aged 18-80 years with a non-traumatic (spontaneous) intracerebral haemorrhage of 20 mL or higher to standard medical care or image-guided MIS plus alteplase (0·3 mg or 1·0 mg every 8 h for up to nine doses) to remove clots using surgical aspiration followed by alteplase clot irrigation. Primary outcomes were all safety outcomes: 30 day mortality, 7 day procedure-related mortality, 72 h symptomatic bleeding, and 30 day brain infections. This trial is registered with ClinicalTrials.gov, number NCT00224770.Between Feb 2, 2006, and April 8, 2013, 96 patients were randomly allocated and completed follow-up: 54 (56%) in the MIS plus alteplase group and 42 (44%) in the standard medical care group. The primary outcomes did not differ between the standard medical care and MIS plus alteplase groups: 30 day mortality (four [9·5%, 95% CI 2·7-22.6] vs eight [14·8%, 6·6-27·1], p=0·542), 7 day mortality (zero [0%, 0-8·4] vs one [1·9%, 0·1-9·9], p=0·562), symptomatic bleeding (one [2·4%, 0·1-12·6] vs five [9·3%, 3·1-20·3], p=0·226), and brain bacterial infections (one [2·4%, 0·1-12·6] vs zero [0%, 0-6·6], p=0·438). Asymptomatic haemorrhages were more common in the MIS plus alteplase group than in the standard medical care group (12 [22·2%; 95% CI 12·0-35·6] vs three [7·1%; 1·5-19·5]; p=0·051).FINDINGSBetween Feb 2, 2006, and April 8, 2013, 96 patients were randomly allocated and completed follow-up: 54 (56%) in the MIS plus alteplase group and 42 (44%) in the standard medical care group. The primary outcomes did not differ between the standard medical care and MIS plus alteplase groups: 30 day mortality (four [9·5%, 95% CI 2·7-22.6] vs eight [14·8%, 6·6-27·1], p=0·542), 7 day mortality (zero [0%, 0-8·4] vs one [1·9%, 0·1-9·9], p=0·562), symptomatic bleeding (one [2·4%, 0·1-12·6] vs five [9·3%, 3·1-20·3], p=0·226), and brain bacterial infections (one [2·4%, 0·1-12·6] vs zero [0%, 0-6·6], p=0·438). Asymptomatic haemorrhages were more common in the MIS plus alteplase group than in the standard medical care group (12 [22·2%; 95% CI 12·0-35·6] vs three [7·1%; 1·5-19·5]; p=0·051).MIS plus alteplase seems to be safe in patients with intracerebral haemorrhage, but increased asymptomatic bleeding is a major cautionary finding. These results, if replicable, could lead to the addition of surgical management as a therapeutic strategy for intracerebral haemorrhage.INTERPRETATIONMIS plus alteplase seems to be safe in patients with intracerebral haemorrhage, but increased asymptomatic bleeding is a major cautionary finding. These results, if replicable, could lead to the addition of surgical management as a therapeutic strategy for intracerebral haemorrhage.National Institute of Neurological Disorders and Stroke, Genentech, and Codman.FUNDINGNational Institute of Neurological Disorders and Stroke, Genentech, and Codman.
Author	Mendelow, A David Graham, R Scott Morgan, Tim C Muschelli, John Awad, Issam Zuccarello, Mario Wijman, Cristanne Kase, Carlos Mayo, Steven W Rosenblum, Michael Lane, Karen Vespa, Paul Martin, Neil Aldrich, E Francois Yenokyan, Gayane Broaddus, William C Mould, W Andrew McBee, Nichol Bistran-Hall, Amanda J Camarata, Paul Gregson, Barbara Huang, Judy Thompson, Richard E Huang, Emily Caron, Jean-Louis Keyl, Penelope Carhuapoma, J Ricardo Hanley, Daniel F Gandhi, Dheeraj Dodd, Robert Thompson, Carol B Ziai, Wendy Janis, Scott Ullman, Natalie
Author_xml	– sequence: 1 givenname: Daniel F surname: Hanley fullname: Hanley, Daniel F email: dhanley@jhmi.edu organization: Department of Neurology, Brain Injury Outcomes Coordinating Center, Johns Hopkins University, Baltimore, MD, USA – sequence: 2 givenname: Richard E surname: Thompson fullname: Thompson, Richard E organization: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA – sequence: 3 givenname: John surname: Muschelli fullname: Muschelli, John organization: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA – sequence: 4 givenname: Michael surname: Rosenblum fullname: Rosenblum, Michael organization: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA – sequence: 5 givenname: Nichol surname: McBee fullname: McBee, Nichol organization: Department of Neurology, Brain Injury Outcomes Coordinating Center, Johns Hopkins University, Baltimore, MD, USA – sequence: 6 givenname: Karen surname: Lane fullname: Lane, Karen organization: Department of Neurology, Brain Injury Outcomes Coordinating Center, Johns Hopkins University, Baltimore, MD, USA – sequence: 7 givenname: Amanda J surname: Bistran-Hall fullname: Bistran-Hall, Amanda J organization: Department of Neurology, Brain Injury Outcomes Coordinating Center, Johns Hopkins University, Baltimore, MD, USA – sequence: 8 givenname: Steven W surname: Mayo fullname: Mayo, Steven W organization: Emissary International, Austin, TX, USA – sequence: 9 givenname: Penelope surname: Keyl fullname: Keyl, Penelope organization: Department of Neurology, Brain Injury Outcomes Coordinating Center, Johns Hopkins University, Baltimore, MD, USA – sequence: 10 givenname: Dheeraj surname: Gandhi fullname: Gandhi, Dheeraj organization: Department of Neuroradiology, University of Maryland, Baltimore, MD, USA – sequence: 11 givenname: Tim C surname: Morgan fullname: Morgan, Tim C organization: Department of Neurology, Brain Injury Outcomes Coordinating Center, Johns Hopkins University, Baltimore, MD, USA – sequence: 12 givenname: Natalie surname: Ullman fullname: Ullman, Natalie organization: Department of Neurology, Brain Injury Outcomes Coordinating Center, Johns Hopkins University, Baltimore, MD, USA – sequence: 13 givenname: W Andrew surname: Mould fullname: Mould, W Andrew organization: Department of Neurology, Brain Injury Outcomes Coordinating Center, Johns Hopkins University, Baltimore, MD, USA – sequence: 14 givenname: J Ricardo surname: Carhuapoma fullname: Carhuapoma, J Ricardo organization: Department of Neurology, Brain Injury Outcomes Coordinating Center, Johns Hopkins University, Baltimore, MD, USA – sequence: 15 givenname: Carlos surname: Kase fullname: Kase, Carlos organization: Department of Neurology, Boston University, Boston, MA, USA – sequence: 16 givenname: Wendy surname: Ziai fullname: Ziai, Wendy organization: Department of Neurology, Brain Injury Outcomes Coordinating Center, Johns Hopkins University, Baltimore, MD, USA – sequence: 17 givenname: Carol B surname: Thompson fullname: Thompson, Carol B organization: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA – sequence: 18 givenname: Gayane surname: Yenokyan fullname: Yenokyan, Gayane organization: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA – sequence: 19 givenname: Emily surname: Huang fullname: Huang, Emily organization: Department of Biostatistics, School of Public Health, Johns Hopkins University, Baltimore, MD, USA – sequence: 20 givenname: William C surname: Broaddus fullname: Broaddus, William C organization: Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA – sequence: 21 givenname: R Scott surname: Graham fullname: Graham, R Scott organization: Department of Neurosurgery, Virginia Commonwealth University, Richmond, VA, USA – sequence: 22 givenname: E Francois surname: Aldrich fullname: Aldrich, E Francois organization: Department of Neurosurgery, University of Maryland, Baltimore, MD, USA – sequence: 23 givenname: Robert surname: Dodd fullname: Dodd, Robert organization: Department of Neurosurgery, Stanford University, Palo Alto, CA, USA – sequence: 24 givenname: Cristanne surname: Wijman fullname: Wijman, Cristanne organization: Department of Neurology, Stanford University, Palo Alto, CA, USA – sequence: 25 givenname: Jean-Louis surname: Caron fullname: Caron, Jean-Louis organization: Department of Neurosurgery, University of Texas, San Antonio, TX, USA – sequence: 26 givenname: Judy surname: Huang fullname: Huang, Judy organization: Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA – sequence: 27 givenname: Paul surname: Camarata fullname: Camarata, Paul organization: Department of Neurosurgery, University of Kansas, Kansas City, KS, USA – sequence: 28 givenname: A David surname: Mendelow fullname: Mendelow, A David organization: Neurosurgery, Newcastle University, Newcastle upon Tyne, UK – sequence: 29 givenname: Barbara surname: Gregson fullname: Gregson, Barbara organization: Neurosurgery, Newcastle University, Newcastle upon Tyne, UK – sequence: 30 givenname: Scott surname: Janis fullname: Janis, Scott organization: National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA – sequence: 31 givenname: Paul surname: Vespa fullname: Vespa, Paul organization: Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA – sequence: 32 givenname: Neil surname: Martin fullname: Martin, Neil organization: Department of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA – sequence: 33 givenname: Issam surname: Awad fullname: Awad, Issam organization: Department of Neurosurgery, University of Chicago, Chicago, IL, USA – sequence: 34 givenname: Mario surname: Zuccarello fullname: Zuccarello, Mario organization: Department of Neurosurgery, University of Cincinnati, Cincinnati, OH, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/27751554$$D View this record in MEDLINE/PubMed
BookMark	eNqNku1qFDEYhYNUbLt6CUrAP1voar7moxUtUqouVPyx9XfIZN50U7OTMZlZmBvqdZrZXSssSAszzJvknCeZnPcYHTS-AYReU_KOEpq_X1BRiJkQjE1pfsIJ42n0DB3tpvPs4KFm7BAdx3hHCKOipC_QISuKjGaZOEL3C2WgG7BqagzGWK30gL3BK9vYlXJuwLZZq2jXgGMfbiEMuHV9xMp10DoVIa2npwtKQ4AqKIeXClY-hKW6BQxrpXvVWd_g6ff54mZ-dXKOFQ5pO7-yEepTrH1ye-fG2rfQzJyqwJ3idjnSGe6CVe4lem6Ui_Bq952gn1-ubi6_za5_fJ1ffr6e6axk3awWVcnPBDO8qgpguS4IJ1mtuckp0VVe1ZyLyiig5KwCJcCUZcFrbjhAoRXwCZpuuW3wv3uInUyn1OCcasD3UdKSF5yVnJGnSDORCV5mSfp2T3rn-9CkH0kqVjLGWXon6M1O1VcrqGUbUgJhkH_DSoJsK9DBxxjAPEgokWNTyE1TyDFxmUabppCj78OeT9tuE0qKzbpH3RdbN6R7X1sIMmoLjYbaBtCdrL19lPBpj6Bdai-t3C8YIP67CxmZJFvIyKD5hjACPv4f8IQD_AFzuPlu
CODEN	LANCAO
CitedBy_id	crossref_primary_10_1016_j_jfma_2024_05_018 crossref_primary_10_23736_S0390_5616_20_04940_1 crossref_primary_10_1016_j_wneu_2019_04_164 crossref_primary_10_1016_j_wneu_2021_01_128 crossref_primary_10_1177_23969873231196381 crossref_primary_10_1016_j_wneu_2022_01_084 crossref_primary_10_1080_14737175_2025_2502048 crossref_primary_10_1007_s13311_019_00722_7 crossref_primary_10_7759_cureus_20613 crossref_primary_10_3390_diagnostics11030576 crossref_primary_10_1007_s40120_021_00279_8 crossref_primary_10_1007_s42399_020_00287_z crossref_primary_10_1016_S1474_4422_19_30069_9 crossref_primary_10_1001_jamaneurol_2025_3151 crossref_primary_10_1007_s12028_020_00916_4 crossref_primary_10_1136_bmjopen_2018_027658 crossref_primary_10_1016_j_clineuro_2024_108192 crossref_primary_10_1136_neurintsurg_2019_015528 crossref_primary_10_23736_S0390_5616_18_04557_5 crossref_primary_10_1016_j_cct_2024_107583 crossref_primary_10_4103_NRR_NRR_D_23_01953 crossref_primary_10_31083_j_jin_2019_02_161 crossref_primary_10_1177_0271678X19892660 crossref_primary_10_1212_CON_0000000000000672 crossref_primary_10_1038_s41598_024_81106_6 crossref_primary_10_23736_S0390_5616_18_04511_3 crossref_primary_10_1016_S0140_6736_18_31878_6 crossref_primary_10_1016_j_wneu_2024_10_107 crossref_primary_10_1080_14737175_2019_1618709 crossref_primary_10_12688_f1000research_16357_1 crossref_primary_10_1136_svn_2024_003893 crossref_primary_10_1016_j_wneu_2025_123816 crossref_primary_10_1186_s13063_017_2041_1 crossref_primary_10_1007_s10143_024_03039_y crossref_primary_10_1016_j_jocn_2025_111196 crossref_primary_10_1016_j_wneu_2019_03_215 crossref_primary_10_1038_s41598_024_54639_z crossref_primary_10_1007_s11701_025_02451_w crossref_primary_10_1016_j_jstrokecerebrovasdis_2020_105050 crossref_primary_10_3389_fneur_2021_789757 crossref_primary_10_1016_j_wneu_2019_08_087 crossref_primary_10_1177_23969873251340815 crossref_primary_10_1016_j_clineuro_2017_09_008 crossref_primary_10_3390_ijms22105132 crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107911 crossref_primary_10_1016_j_ncl_2021_02_002 crossref_primary_10_1007_s10143_022_01782_8 crossref_primary_10_1016_j_jstrokecerebrovasdis_2019_05_003 crossref_primary_10_3389_fneur_2022_817386 crossref_primary_10_1161_STROKEAHA_121_037298 crossref_primary_10_1186_s12931_023_02638_5 crossref_primary_10_1016_j_jconrel_2025_01_007 crossref_primary_10_1016_j_wneu_2019_12_074 crossref_primary_10_3390_life13030846 crossref_primary_10_4103_jets_jets_158_23 crossref_primary_10_1007_s12028_021_01311_3 crossref_primary_10_1038_s41598_022_26176_0 crossref_primary_10_3389_fneur_2021_789060 crossref_primary_10_1371_journal_pone_0210810 crossref_primary_10_1016_S0140_6736_19_30309_5 crossref_primary_10_1186_s41984_023_00246_5 crossref_primary_10_1016_j_wneu_2019_04_258 crossref_primary_10_1177_0271678X17725431 crossref_primary_10_1007_s10439_022_02934_z crossref_primary_10_1111_jon_12997 crossref_primary_10_1016_S1474_4422_18_30323_5 crossref_primary_10_3389_fneur_2022_859894 crossref_primary_10_1016_j_clineuro_2024_108287 crossref_primary_10_1161_STROKEAHA_121_035421 crossref_primary_10_1016_j_jstrokecerebrovasdis_2020_105073 crossref_primary_10_1093_ons_opz308 crossref_primary_10_1186_s44158_023_00131_5 crossref_primary_10_1016_j_inat_2023_101821 crossref_primary_10_3390_brainsci15050455 crossref_primary_10_1007_s00701_023_05599_2 crossref_primary_10_1038_s41598_020_67456_x crossref_primary_10_1136_bcr_2017_013188 crossref_primary_10_1016_j_neuchi_2020_11_004 crossref_primary_10_1136_neurintsurg_2017_013719 crossref_primary_10_1161_STROKEAHA_119_025443 crossref_primary_10_1093_neuros_nyz077 crossref_primary_10_1016_j_mri_2023_07_015 crossref_primary_10_1161_STROKEAHA_116_015342 crossref_primary_10_1080_01616412_2025_2556960 crossref_primary_10_1136_svn_2025_004234 crossref_primary_10_1161_STROKEAHA_117_017702 crossref_primary_10_3171_2020_6_PEDS2042 crossref_primary_10_1136_neurintsurg_2020_017077 crossref_primary_10_1007_s10143_023_02237_4 crossref_primary_10_3389_fneur_2022_727702 crossref_primary_10_1161_STROKEAHA_119_026764 crossref_primary_10_3389_fneur_2017_00645 crossref_primary_10_1007_s00701_020_04477_5 crossref_primary_10_1016_j_jns_2019_02_032 crossref_primary_10_1016_j_jstrokecerebrovasdis_2021_105934 crossref_primary_10_1016_j_wneu_2018_05_221 crossref_primary_10_1016_j_wneu_2020_09_016 crossref_primary_10_1016_j_ncl_2021_12_001 crossref_primary_10_1007_s00063_017_0361_2 crossref_primary_10_1016_j_wneu_2018_01_006 crossref_primary_10_3171_2020_8_JNS201839 crossref_primary_10_1002_acn3_51443 crossref_primary_10_1007_s12975_020_00798_w crossref_primary_10_3389_fneur_2022_755501 crossref_primary_10_1093_neuros_nyz533 crossref_primary_10_1001_jama_2019_2413 crossref_primary_10_1002_ana_27107 crossref_primary_10_1177_0271678X20923551 crossref_primary_10_7759_cureus_12227 crossref_primary_10_1055_s_0040_1722639 crossref_primary_10_1212_WNL_0000000000007269 crossref_primary_10_1161_STROKEAHA_119_027198 crossref_primary_10_1007_s10143_025_03574_2 crossref_primary_10_3389_fneur_2022_915370 crossref_primary_10_3389_fneur_2023_1068829 crossref_primary_10_1007_s00701_024_05958_7 crossref_primary_10_1186_s12987_018_0096_3 crossref_primary_10_1007_s12028_020_00996_2 crossref_primary_10_1016_j_jstrokecerebrovasdis_2019_104361 crossref_primary_10_1186_s13063_024_08534_7 crossref_primary_10_1007_s10143_024_02479_w crossref_primary_10_1186_s12893_024_02644_4 crossref_primary_10_1016_j_jocn_2018_10_001 crossref_primary_10_1016_S0140_6736_24_00642_1 crossref_primary_10_1161_STR_0000000000000407 crossref_primary_10_1016_S0140_6736_19_31410_2 crossref_primary_10_1016_j_jns_2020_117020 crossref_primary_10_1227_ons_0000000000000304 crossref_primary_10_1002_ana_25732 crossref_primary_10_1155_2020_6503038 crossref_primary_10_1002_ana_25356 crossref_primary_10_3389_fnins_2022_850179 crossref_primary_10_1093_neuros_nyx123 crossref_primary_10_3389_fneur_2022_1032343 crossref_primary_10_1002_adma_202006047 crossref_primary_10_1016_j_wnsx_2024_100316 crossref_primary_10_1016_j_clineuro_2023_107672 crossref_primary_10_1016_j_wneu_2022_01_123 crossref_primary_10_1371_journal_pone_0304398 crossref_primary_10_3389_fneur_2023_1131283 crossref_primary_10_1097_CCM_0000000000004933 crossref_primary_10_1016_j_wneu_2017_09_027 crossref_primary_10_1093_neuros_nyz551 crossref_primary_10_3389_fneur_2019_00991 crossref_primary_10_1093_ons_opaa306 crossref_primary_10_1136_jnis_2024_022237 crossref_primary_10_1038_s41598_025_00469_6 crossref_primary_10_1016_j_trsl_2019_04_009 crossref_primary_10_1177_1747493019839280 crossref_primary_10_3389_fneur_2021_742959 crossref_primary_10_1007_s12028_017_0498_0 crossref_primary_10_1017_cjn_2021_185 crossref_primary_10_1177_0271678X17719180 crossref_primary_10_1136_neurintsurg_2019_015362 crossref_primary_10_3389_fneur_2020_00426 crossref_primary_10_1007_s11940_021_00678_0 crossref_primary_10_1007_s00701_018_3517_9 crossref_primary_10_1055_a_2503_2742 crossref_primary_10_4103_0028_3886_344635 crossref_primary_10_1016_S1474_4422_16_30245_9 crossref_primary_10_1007_s12028_020_00962_y crossref_primary_10_1080_02688697_2024_2344759 crossref_primary_10_1016_S0140_6736_19_30195_3 crossref_primary_10_1155_2019_7403104 crossref_primary_10_1016_j_jocn_2019_12_031 crossref_primary_10_3389_fnins_2022_947282 crossref_primary_10_1016_j_jstrokecerebrovasdis_2019_06_013 crossref_primary_10_1016_S0140_6736_19_31416_3 crossref_primary_10_1136_svn_2018_000200 crossref_primary_10_3389_fneur_2023_1188717 crossref_primary_10_1007_s10143_020_01252_z crossref_primary_10_1111_biom_13101 crossref_primary_10_3390_jcm12041533 crossref_primary_10_1016_j_clineuro_2019_105617 crossref_primary_10_1007_s12975_018_0628_9 crossref_primary_10_3892_etm_2025_12797 crossref_primary_10_1097_MCC_0000000000000695 crossref_primary_10_1161_SVIN_123_001165 crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107878 crossref_primary_10_1007_s00062_024_01406_2 crossref_primary_10_1016_j_wneu_2024_06_058 crossref_primary_10_1016_j_wneu_2018_07_145 crossref_primary_10_1212_WNL_0000000000005167 crossref_primary_10_3171_2022_3_JNS22286 crossref_primary_10_1016_j_jstrokecerebrovasdis_2019_104320 crossref_primary_10_3389_fneur_2023_1126958 crossref_primary_10_1016_j_wneu_2018_12_058 crossref_primary_10_1016_j_neuropharm_2017_09_033 crossref_primary_10_3390_ijms23042306 crossref_primary_10_1016_j_wneu_2017_10_049 crossref_primary_10_1016_j_nec_2017_11_005 crossref_primary_10_1016_j_jstrokecerebrovasdis_2023_107445 crossref_primary_10_1016_j_medici_2017_07_006 crossref_primary_10_1016_j_jstrokecerebrovasdis_2022_106975 crossref_primary_10_1016_j_wneu_2018_11_260 crossref_primary_10_25259_SNI_887_2020 crossref_primary_10_1016_S0140_6736_16_32410_2 crossref_primary_10_1007_s12028_023_01886_z crossref_primary_10_1136_svn_2019_000264 crossref_primary_10_1016_S1474_4422_24_00424_1 crossref_primary_10_1007_s11910_020_01080_0 crossref_primary_10_7861_clinmedicine_18_2_s9 crossref_primary_10_1007_s12028_022_01667_0 crossref_primary_10_3389_fneur_2021_722924 crossref_primary_10_1055_a_2344_8695 crossref_primary_10_1007_s00115_019_0777_4 crossref_primary_10_1227_ons_0000000000000161 crossref_primary_10_1007_s13311_020_00902_w crossref_primary_10_1155_2021_9931742 crossref_primary_10_1002_adfm_202214485 crossref_primary_10_1186_s13054_020_2749_2 crossref_primary_10_1080_00207454_2020_1713773 crossref_primary_10_3171_2019_3_JNS19545 crossref_primary_10_1038_s41598_025_92775_2 crossref_primary_10_3389_fneur_2017_00371 crossref_primary_10_1136_neurintsurg_2017_013188_rep crossref_primary_10_3389_fneur_2023_1126585 crossref_primary_10_1177_0271678X18802119 crossref_primary_10_3389_fneur_2017_00004 crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107804 crossref_primary_10_1016_j_wneu_2018_05_170 crossref_primary_10_1161_STROKEAHA_118_020688 crossref_primary_10_1016_j_jstrokecerebrovasdis_2023_107309 crossref_primary_10_1055_a_2000_3783 crossref_primary_10_1177_2516608518821557 crossref_primary_10_1212_WNL_0000000000207728 crossref_primary_10_1007_s12028_023_01869_0 crossref_primary_10_1111_jebm_12386 crossref_primary_10_1177_17474930221142742 crossref_primary_10_3389_fneur_2021_703189 crossref_primary_10_25259_JNRP_65_2025 crossref_primary_10_3389_fimmu_2021_740632 crossref_primary_10_1016_j_clineuro_2019_03_013 crossref_primary_10_1177_15459683221137342 crossref_primary_10_1177_17474930211044870 crossref_primary_10_1002_14651858_CD015387_pub2 crossref_primary_10_1016_j_jocn_2024_07_004 crossref_primary_10_3390_jcm12124005 crossref_primary_10_1007_s11910_018_0836_4 crossref_primary_10_1161_STROKEAHA_118_024578 crossref_primary_10_1007_s00701_019_04154_2 crossref_primary_10_1093_neuros_nyz250 crossref_primary_10_1097_ANA_0000000000000493 crossref_primary_10_1016_S1474_4422_18_30253_9 crossref_primary_10_1227_ONS_0000000000000005 crossref_primary_10_1016_j_eclinm_2024_102999 crossref_primary_10_1007_s12021_020_09493_5 crossref_primary_10_1007_s11910_017_0783_5 crossref_primary_10_1016_j_ncl_2017_06_009 crossref_primary_10_3389_fneur_2022_1054106 crossref_primary_10_13004_kjnt_2025_21_e25 crossref_primary_10_1016_j_irbm_2025_100896 crossref_primary_10_1097_JCMA_0000000000000015 crossref_primary_10_1177_0271678X17753590 crossref_primary_10_1080_02688697_2020_1773395 crossref_primary_10_1016_j_wneu_2024_03_107 crossref_primary_10_1212_WNL_0000000000207735 crossref_primary_10_1186_s12893_023_02227_9 crossref_primary_10_1016_j_wneu_2025_123845 crossref_primary_10_1186_s12883_021_02181_0 crossref_primary_10_1016_j_wneu_2022_09_109 crossref_primary_10_1093_biostatistics_kxw049 crossref_primary_10_1093_ons_opaa390 crossref_primary_10_1080_14737175_2019_1623671 crossref_primary_10_1177_2396987319848203 crossref_primary_10_2147_IJGM_S289238 crossref_primary_10_1007_s11701_025_02408_z crossref_primary_10_1096_fj_201902478R crossref_primary_10_1016_j_wneu_2018_09_172 crossref_primary_10_1136_jnis_2023_020787
Cites_doi	10.1161/STROKEAHA.111.640284 10.1016/S0140-6736(13)60986-1 10.1097/00003246-199903000-00045 10.1093/biomet/ass013 10.1002/sim.6197 10.1055/s-2000-8411 10.1159/000094831 10.1161/STROKEAHA.110.586156 10.1161/01.STR.31.4.834 10.1161/01.STR.30.9.1833 10.1002/14651858.CD009372.pub2 10.1161/STROKEAHA.112.670653 10.1002/sim.3148 10.1080/10543400903243009 10.1007/s00415-011-5902-7 10.1161/STROKEAHA.108.538967 10.1161/STROKEAHA.111.000411 10.1002/sim.6507 10.1186/1477-7525-8-49 10.1016/S0140-6736(05)70233-6 10.1056/NEJMoa1214609 10.3171/jns.1999.90.3.0491 10.1016/S2214-109X(13)70089-5 10.1056/NEJMoa0707534 10.1161/CIRCULATIONAHA.107.183689 10.1007/978-3-211-09469-3_30 10.1212/01.wnl.0000208408.98482.99 10.1111/ijs.12309 10.1161/STROKEAHA.112.667535 10.1161/STR.0b013e3181ec611b
ContentType	Journal Article
Copyright	2016 Elsevier Ltd Elsevier Ltd Copyright © 2016 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Nov 01, 2016
Copyright_xml	– notice: 2016 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2016 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Nov 01, 2016
CorporateAuthor	MISTIE Investigators
CorporateAuthor_xml	– name: MISTIE Investigators
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 88G 8AO 8C2 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8
DOI	10.1016/S1474-4422(16)30234-4
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Psychology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest One Psychology Neurosciences Abstracts MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1474-4465
EndPage	1237
ExternalDocumentID	4213291121 27751554 10_1016_S1474_4422_16_30234_4 S1474442216302344 1_s2_0_S1474442216302344
Genre	Multicenter Study Clinical Trial, Phase II Randomized Controlled Trial Journal Article
GrantInformation	National Institute of Neurological Disorders and Stroke, Genentech, and Codman.
GrantInformation_xml	– fundername: NINDS NIH HHS grantid: U01 NS062851 – fundername: NIA NIH HHS grantid: T32 AG000247 – fundername: NINDS NIH HHS grantid: R01 NS046309
GroupedDBID	--- --K --M -RU .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 8AO 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABIVO ABJNI ABMAC ABMZM ABOCM ABTEW ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGWIK AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP AXJTR AZQEC BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ HF~ HMCUK HVGLF HZ~ IHE J1W JCF KOM M1P M2M M41 MO0 N9A NAPCQ O-L O9- OP~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ ROL RPZ SDG SEL SES SPCBC SSH SSN SSZ T5K TLN UHS UKHRP UV1 WOW XBR Z5R ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF AADPK ABLVK ABYKQ AJBFU ZA5 9DU AAYXX AFFHD CITATION CGR CUY CVF ECM EIF NPM 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8
ID	FETCH-LOGICAL-c582t-d4b83942f3bb7e26c70305dc3f610cb6bd334bfae109bea4ef8873d3f3ee7cae3
IEDL.DBID	BENPR
ISICitedReferencesCount	310
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000386315700018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1474-4422 1474-4465
IngestDate	Sun Nov 09 10:22:34 EST 2025 Sun Nov 09 12:23:54 EST 2025 Mon Oct 06 16:53:21 EDT 2025 Wed Feb 19 02:40:33 EST 2025 Sat Nov 29 03:40:58 EST 2025 Tue Nov 18 21:58:39 EST 2025 Fri Feb 23 02:28:58 EST 2024 Sun Feb 23 10:18:50 EST 2025 Tue Oct 14 19:33:16 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	12
Language	English
License	Copyright © 2016 Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c582t-d4b83942f3bb7e26c70305dc3f610cb6bd334bfae109bea4ef8873d3f3ee7cae3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
OpenAccessLink	http://doi.org/10.1016/S1474-4422(16)30234-4
PMID	27751554
PQID	1828223222
PQPubID	26255
PageCount	10
ParticipantIDs	proquest_miscellaneous_1837328320 proquest_miscellaneous_1835454385 proquest_journals_1828223222 pubmed_primary_27751554 crossref_primary_10_1016_S1474_4422_16_30234_4 crossref_citationtrail_10_1016_S1474_4422_16_30234_4 elsevier_sciencedirect_doi_10_1016_S1474_4422_16_30234_4 elsevier_clinicalkeyesjournals_1_s2_0_S1474442216302344 elsevier_clinicalkey_doi_10_1016_S1474_4422_16_30234_4
PublicationCentury	2000
PublicationDate	2016-11-01
PublicationDateYYYYMMDD	2016-11-01
PublicationDate_xml	– month: 11 year: 2016 text: 2016-11-01 day: 01
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London
PublicationTitle	Lancet neurology
PublicationTitleAlternate	Lancet Neurol
PublicationYear	2016
Publisher	Elsevier Ltd Elsevier Limited
Publisher_xml	– name: Elsevier Ltd – name: Elsevier Limited
References	Morgan, Dawson, Spengler (bib20) 2013; 44 Morgan, Zuccarello, Narayan, Keyl, Lane, Hanley (bib11) 2008; 105 Rotnitzky, Lei, Sued, Robins (bib21) 2012; 99 Tuhrim, Horowitz, Sacher (bib24) 1999; 27 Davis, Broderick, Hennerici (bib25) 2006; 66 Wagner, Xi, Hua (bib10) 1999; 90 Steiner, Al-Shahi Salman, Beer (bib30) 2014; 9 Mayer, Brun, Begtrup (bib7) 2008; 358 Rohde, Rohde, Reinges, Mayfrank, Gilsbach (bib14) 2000; 43 Mendelow, Gregson, Rowan, Murray, Gholkar, Mitchell (bib6) 2013; 382 Morgenstern, Hemphill, Anderson (bib18) 2010; 41 Sauerbrei, Royston, Binder (bib26) 2007; 26 Zhou, Zhang, Liu (bib31) 2011; 258 Steiner, Kaste, Forsting (bib29) 2006; 22 Krishnamurthi, Feigin, Forouzanfar (bib1) 2013; 1 Yan, Lee, Li (bib27) 2009; 19 Zhou, Chen, Li (bib32) 2012; 43 Ziai, Stadnik, Zhang (bib33) 2014; 45 Gregson, Broderick, Auer (bib34) 2012; 43 Hachinski, Donnan, Gorelick (bib2) 2010; 41 Mould, Carhuapoma, Muschelli (bib9) 2013; 44 Anderson, Heeley, Huang (bib8) 2013; 368 Colantuoni, Rosenblum (bib22) 2015 Mendelow, Gregson, Fernandes (bib5) 2005; 365 Cadilhac, Dewey, Vos, Carter, Thrift (bib3) 2010; 8 Christensen, Mayer, Ferran (bib4) 2009; 40 Josephson, White, Krishan, Al-Shahi Salman (bib17) 2014; 9 Broderick, Connolly, Feldmann (bib19) 2007; 116 Hanley DF, Lane K, Broaddus WC, et al. MISTIE trial: 365-day results demonstrate improved outcomes and cost benefit. International Stroke Conference; Honolulu, Hawaii, USA; Feb 6–8, 2013 (abstr L21). bib16 Montes, Wong, Fayad, Awad (bib13) 2000; 31 Cleveland, Grosse, Shyu (bib23) 1992 Liublinska, Rubin (bib28) 2014; 33 Zuccarello, Brott, Derex (bib15) 1999; 30 Montes (10.1016/S1474-4422(16)30234-4_bib13) 2000; 31 Yan (10.1016/S1474-4422(16)30234-4_bib27) 2009; 19 Zhou (10.1016/S1474-4422(16)30234-4_bib31) 2011; 258 Anderson (10.1016/S1474-4422(16)30234-4_bib8) 2013; 368 Morgenstern (10.1016/S1474-4422(16)30234-4_bib18) 2010; 41 Colantuoni (10.1016/S1474-4422(16)30234-4_bib22) 2015 Davis (10.1016/S1474-4422(16)30234-4_bib25) 2006; 66 Rotnitzky (10.1016/S1474-4422(16)30234-4_bib21) 2012; 99 Sauerbrei (10.1016/S1474-4422(16)30234-4_bib26) 2007; 26 Christensen (10.1016/S1474-4422(16)30234-4_bib4) 2009; 40 10.1016/S1474-4422(16)30234-4_bib12 Mendelow (10.1016/S1474-4422(16)30234-4_bib6) 2013; 382 Steiner (10.1016/S1474-4422(16)30234-4_bib30) 2014; 9 Mendelow (10.1016/S1474-4422(16)30234-4_bib5) 2005; 365 Rohde (10.1016/S1474-4422(16)30234-4_bib14) 2000; 43 Zhou (10.1016/S1474-4422(16)30234-4_bib32) 2012; 43 Gregson (10.1016/S1474-4422(16)30234-4_bib34) 2012; 43 Cadilhac (10.1016/S1474-4422(16)30234-4_bib3) 2010; 8 Josephson (10.1016/S1474-4422(16)30234-4_bib17) 2014; 9 Broderick (10.1016/S1474-4422(16)30234-4_bib19) 2007; 116 Krishnamurthi (10.1016/S1474-4422(16)30234-4_bib1) 2013; 1 Hachinski (10.1016/S1474-4422(16)30234-4_bib2) 2010; 41 Morgan (10.1016/S1474-4422(16)30234-4_bib20) 2013; 44 Zuccarello (10.1016/S1474-4422(16)30234-4_bib15) 1999; 30 Ziai (10.1016/S1474-4422(16)30234-4_bib33) 2014; 45 Tuhrim (10.1016/S1474-4422(16)30234-4_bib24) 1999; 27 Morgan (10.1016/S1474-4422(16)30234-4_bib11) 2008; 105 Wagner (10.1016/S1474-4422(16)30234-4_bib10) 1999; 90 Cleveland (10.1016/S1474-4422(16)30234-4_bib23) 1992 Mould (10.1016/S1474-4422(16)30234-4_bib9) 2013; 44 Liublinska (10.1016/S1474-4422(16)30234-4_bib28) 2014; 33 Steiner (10.1016/S1474-4422(16)30234-4_bib29) 2006; 22 Mayer (10.1016/S1474-4422(16)30234-4_bib7) 2008; 358 23391763 - Stroke. 2013 Mar;44(3):627-34 22989500 - Stroke. 2012 Nov;43(11):2923-30 23370203 - Stroke. 2013 Mar;44(3):635-41 16636233 - Neurology. 2006 Apr 25;66(8):1175-81 19066101 - Acta Neurochir Suppl. 2008;105:147-51 21340523 - J Neurol. 2011 Apr;258(4):661-9 27751536 - Lancet Neurol. 2016 Nov;15(12):1197-1199 16926557 - Cerebrovasc Dis. 2006;22(4):294-316 17938297 - Circulation. 2007 Oct 16;116(16):e391-413 25872751 - Stat Med. 2015 Aug 15;34(18):2602-17 24845086 - Stat Med. 2014 Oct 30;33(24):4170-85 20651276 - Stroke. 2010 Sep;41(9):2108-29 25177839 - Cochrane Database Syst Rev. 2014 Sep 01;(9):CD009372 23843666 - Biometrika. 2012 Jun;99(2):439-456 22511006 - Stroke. 2012 Jun;43(6):1496-504 23726393 - Lancet. 2013 Aug 3;382(9890):397-408 10471432 - Stroke. 1999 Sep;30(9):1833-9 23713578 - N Engl J Med. 2013 Jun 20;368(25):2355-65 25156220 - Int J Stroke. 2014 Oct;9(7):840-55 10067918 - J Neurosurg. 1999 Mar;90(3):491-8 19265046 - Stroke. 2009 May;40(5):1677-82 25104492 - Lancet Glob Health. 2013 Nov;1(5):e259-81 10753984 - Stroke. 2000 Apr;31(4):834-40 18058845 - Stat Med. 2007 Dec 30;26(30):5512-28 20498453 - Stroke. 2010 Jun;41(6):1084-99 10794561 - Minim Invasive Neurosurg. 2000 Mar;43(1):9-17 20470370 - Health Qual Life Outcomes. 2010 May 14;8:49 10199544 - Crit Care Med. 1999 Mar;27(3):617-21 15680453 - Lancet. 2005 Jan 29-Feb 4;365(9457):387-97 18480205 - N Engl J Med. 2008 May 15;358(20):2127-37 20183466 - J Biopharm Stat. 2009 Nov;19(6):1085-98
References_xml	– start-page: 2602 year: 2015 end-page: 2617 ident: bib22 article-title: Leveraging prognostic baseline variables to gain precision in randomized trials publication-title: Stat Med – volume: 368 start-page: 2355 year: 2013 end-page: 2365 ident: bib8 article-title: Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage publication-title: N Engl J Med – volume: 43 start-page: 1496 year: 2012 end-page: 1504 ident: bib34 article-title: Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage publication-title: Stroke – volume: 90 start-page: 491 year: 1999 end-page: 498 ident: bib10 article-title: Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection publication-title: J Neurosurg – volume: 66 start-page: 1175 year: 2006 end-page: 1181 ident: bib25 article-title: Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage publication-title: Neurology – volume: 26 start-page: 5512 year: 2007 end-page: 5528 ident: bib26 article-title: Selection of important variables and determination of functional form for continuous predictors in multivariable model building publication-title: Stat Med – volume: 43 start-page: 2923 year: 2012 end-page: 2930 ident: bib32 article-title: Minimally invasive surgery for spontaneous supratentorial intracerebral hemorrhage: a meta-analysis of randomized controlled trials publication-title: Stroke – volume: 45 start-page: A35 year: 2014 ident: bib33 article-title: Stabilizing bleeding prior to acute therapies for spontaneous intracerebral hemorrhage publication-title: Stroke – volume: 105 start-page: 147 year: 2008 end-page: 151 ident: bib11 article-title: Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial publication-title: Acta Neurochir Suppl – volume: 1 start-page: e259 year: 2013 end-page: e281 ident: bib1 article-title: Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 publication-title: Lancet Glob Health – volume: 8 start-page: 49 year: 2010 ident: bib3 article-title: The health loss from ischemic stroke and intracerebral hemorrhage: evidence from the North East Melbourne Stroke Incidence Study (NEMESIS) publication-title: Health Qual Life Outcomes – volume: 19 start-page: 1085 year: 2009 end-page: 1098 ident: bib27 article-title: Missing data handling methods in medical device clinical trials publication-title: J Biopharm Stat – volume: 99 start-page: 439 year: 2012 end-page: 456 ident: bib21 article-title: Improved double-robust estimation in missing data and causal inference models publication-title: Biometrika – volume: 41 start-page: 1084 year: 2010 end-page: 1099 ident: bib2 article-title: Stroke: working toward a prioritized world agenda publication-title: Stroke – volume: 22 start-page: 294 year: 2006 end-page: 316 ident: bib29 article-title: Recommendations for the management of intracranial haemorrhage—part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee publication-title: Cerebrovasc Dis – volume: 358 start-page: 2127 year: 2008 end-page: 2137 ident: bib7 article-title: Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage publication-title: N Engl J Med – volume: 44 start-page: 627 year: 2013 end-page: 634 ident: bib9 article-title: Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema publication-title: Stroke – start-page: 309 year: 1992 end-page: 376 ident: bib23 article-title: Local regression models publication-title: Statistical models – volume: 9 start-page: 840 year: 2014 end-page: 855 ident: bib30 article-title: European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage publication-title: Int J Stroke – volume: 30 start-page: 1833 year: 1999 end-page: 1839 ident: bib15 article-title: Early surgical treatment for supratentorial intracerebral hemorrhage: a randomized feasibility study publication-title: Stroke – volume: 44 start-page: 635 year: 2013 end-page: 641 ident: bib20 article-title: The Modified Graeb Score: an enhanced tool for intraventricular hemorrhage measurement and prediction of functional outcome publication-title: Stroke – volume: 43 start-page: 9 year: 2000 end-page: 17 ident: bib14 article-title: Frameless stereotactically guided catheter placement and fibrinolytic therapy for spontaneous intracerebral hematomas: technical aspects and initial clinical results publication-title: Minim Invasive Neurosurg – reference: Hanley DF, Lane K, Broaddus WC, et al. MISTIE trial: 365-day results demonstrate improved outcomes and cost benefit. International Stroke Conference; Honolulu, Hawaii, USA; Feb 6–8, 2013 (abstr L21). – volume: 40 start-page: 1677 year: 2009 end-page: 1682 ident: bib4 article-title: Quality of life after intracerebral hemorrhage: results of the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial publication-title: Stroke – volume: 27 start-page: 617 year: 1999 end-page: 621 ident: bib24 article-title: Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage publication-title: Crit Care Med – volume: 365 start-page: 387 year: 2005 end-page: 397 ident: bib5 article-title: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial publication-title: Lancet – ident: bib16 article-title: Minimally invasive surgery and rtPA for intracerebral hemorrhage evacuation (MISTIE) – volume: 33 start-page: 4170 year: 2014 end-page: 4185 ident: bib28 article-title: Sensitivity analysis for a partially missing binary outcome in a two-arm randomized clinical trial publication-title: Stat Med – volume: 382 start-page: 397 year: 2013 end-page: 408 ident: bib6 article-title: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial publication-title: Lancet – volume: 31 start-page: 834 year: 2000 end-page: 840 ident: bib13 article-title: Stereotactic computed tomographic-guided aspiration and thrombolysis of intracerebral hematoma: protocol and preliminary experience publication-title: Stroke – volume: 41 start-page: 2108 year: 2010 end-page: 2129 ident: bib18 article-title: Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association publication-title: Stroke – volume: 258 start-page: 661 year: 2011 end-page: 669 ident: bib31 article-title: Minimally invasive stereotactic puncture and thrombolysis therapy improves long-term outcome after acute intracerebral hemorrhage publication-title: J Neurol – volume: 116 start-page: e391 year: 2007 end-page: e413 ident: bib19 article-title: Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group publication-title: Circulation – volume: 9 year: 2014 ident: bib17 article-title: Computed tomography angiography or magnetic resonance angiography for detection of intracranial vascular malformations in patients with intracerebral haemorrhage publication-title: Cochrane Database Syst Rev – volume: 43 start-page: 1496 year: 2012 ident: 10.1016/S1474-4422(16)30234-4_bib34 article-title: Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage publication-title: Stroke doi: 10.1161/STROKEAHA.111.640284 – volume: 382 start-page: 397 year: 2013 ident: 10.1016/S1474-4422(16)30234-4_bib6 article-title: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(13)60986-1 – volume: 27 start-page: 617 year: 1999 ident: 10.1016/S1474-4422(16)30234-4_bib24 article-title: Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage publication-title: Crit Care Med doi: 10.1097/00003246-199903000-00045 – volume: 99 start-page: 439 year: 2012 ident: 10.1016/S1474-4422(16)30234-4_bib21 article-title: Improved double-robust estimation in missing data and causal inference models publication-title: Biometrika doi: 10.1093/biomet/ass013 – volume: 33 start-page: 4170 year: 2014 ident: 10.1016/S1474-4422(16)30234-4_bib28 article-title: Sensitivity analysis for a partially missing binary outcome in a two-arm randomized clinical trial publication-title: Stat Med doi: 10.1002/sim.6197 – volume: 43 start-page: 9 year: 2000 ident: 10.1016/S1474-4422(16)30234-4_bib14 article-title: Frameless stereotactically guided catheter placement and fibrinolytic therapy for spontaneous intracerebral hematomas: technical aspects and initial clinical results publication-title: Minim Invasive Neurosurg doi: 10.1055/s-2000-8411 – volume: 22 start-page: 294 year: 2006 ident: 10.1016/S1474-4422(16)30234-4_bib29 article-title: Recommendations for the management of intracranial haemorrhage—part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee publication-title: Cerebrovasc Dis doi: 10.1159/000094831 – volume: 41 start-page: 1084 year: 2010 ident: 10.1016/S1474-4422(16)30234-4_bib2 article-title: Stroke: working toward a prioritized world agenda publication-title: Stroke doi: 10.1161/STROKEAHA.110.586156 – start-page: 309 year: 1992 ident: 10.1016/S1474-4422(16)30234-4_bib23 article-title: Local regression models – volume: 31 start-page: 834 year: 2000 ident: 10.1016/S1474-4422(16)30234-4_bib13 article-title: Stereotactic computed tomographic-guided aspiration and thrombolysis of intracerebral hematoma: protocol and preliminary experience publication-title: Stroke doi: 10.1161/01.STR.31.4.834 – volume: 30 start-page: 1833 year: 1999 ident: 10.1016/S1474-4422(16)30234-4_bib15 article-title: Early surgical treatment for supratentorial intracerebral hemorrhage: a randomized feasibility study publication-title: Stroke doi: 10.1161/01.STR.30.9.1833 – volume: 9 year: 2014 ident: 10.1016/S1474-4422(16)30234-4_bib17 article-title: Computed tomography angiography or magnetic resonance angiography for detection of intracranial vascular malformations in patients with intracerebral haemorrhage publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD009372.pub2 – volume: 44 start-page: 635 year: 2013 ident: 10.1016/S1474-4422(16)30234-4_bib20 article-title: The Modified Graeb Score: an enhanced tool for intraventricular hemorrhage measurement and prediction of functional outcome publication-title: Stroke doi: 10.1161/STROKEAHA.112.670653 – volume: 26 start-page: 5512 year: 2007 ident: 10.1016/S1474-4422(16)30234-4_bib26 article-title: Selection of important variables and determination of functional form for continuous predictors in multivariable model building publication-title: Stat Med doi: 10.1002/sim.3148 – volume: 19 start-page: 1085 year: 2009 ident: 10.1016/S1474-4422(16)30234-4_bib27 article-title: Missing data handling methods in medical device clinical trials publication-title: J Biopharm Stat doi: 10.1080/10543400903243009 – volume: 258 start-page: 661 year: 2011 ident: 10.1016/S1474-4422(16)30234-4_bib31 article-title: Minimally invasive stereotactic puncture and thrombolysis therapy improves long-term outcome after acute intracerebral hemorrhage publication-title: J Neurol doi: 10.1007/s00415-011-5902-7 – volume: 40 start-page: 1677 year: 2009 ident: 10.1016/S1474-4422(16)30234-4_bib4 article-title: Quality of life after intracerebral hemorrhage: results of the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial publication-title: Stroke doi: 10.1161/STROKEAHA.108.538967 – volume: 45 start-page: A35 issue: suppl 1 year: 2014 ident: 10.1016/S1474-4422(16)30234-4_bib33 article-title: Stabilizing bleeding prior to acute therapies for spontaneous intracerebral hemorrhage publication-title: Stroke – volume: 44 start-page: 627 year: 2013 ident: 10.1016/S1474-4422(16)30234-4_bib9 article-title: Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema publication-title: Stroke doi: 10.1161/STROKEAHA.111.000411 – start-page: 2602 year: 2015 ident: 10.1016/S1474-4422(16)30234-4_bib22 article-title: Leveraging prognostic baseline variables to gain precision in randomized trials publication-title: Stat Med doi: 10.1002/sim.6507 – volume: 8 start-page: 49 year: 2010 ident: 10.1016/S1474-4422(16)30234-4_bib3 article-title: The health loss from ischemic stroke and intracerebral hemorrhage: evidence from the North East Melbourne Stroke Incidence Study (NEMESIS) publication-title: Health Qual Life Outcomes doi: 10.1186/1477-7525-8-49 – volume: 365 start-page: 387 year: 2005 ident: 10.1016/S1474-4422(16)30234-4_bib5 article-title: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(05)70233-6 – volume: 368 start-page: 2355 year: 2013 ident: 10.1016/S1474-4422(16)30234-4_bib8 article-title: Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage publication-title: N Engl J Med doi: 10.1056/NEJMoa1214609 – volume: 90 start-page: 491 year: 1999 ident: 10.1016/S1474-4422(16)30234-4_bib10 article-title: Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection publication-title: J Neurosurg doi: 10.3171/jns.1999.90.3.0491 – ident: 10.1016/S1474-4422(16)30234-4_bib12 – volume: 1 start-page: e259 year: 2013 ident: 10.1016/S1474-4422(16)30234-4_bib1 article-title: Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(13)70089-5 – volume: 358 start-page: 2127 year: 2008 ident: 10.1016/S1474-4422(16)30234-4_bib7 article-title: Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage publication-title: N Engl J Med doi: 10.1056/NEJMoa0707534 – volume: 116 start-page: e391 year: 2007 ident: 10.1016/S1474-4422(16)30234-4_bib19 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.183689 – volume: 105 start-page: 147 year: 2008 ident: 10.1016/S1474-4422(16)30234-4_bib11 article-title: Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial publication-title: Acta Neurochir Suppl doi: 10.1007/978-3-211-09469-3_30 – volume: 66 start-page: 1175 year: 2006 ident: 10.1016/S1474-4422(16)30234-4_bib25 article-title: Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage publication-title: Neurology doi: 10.1212/01.wnl.0000208408.98482.99 – volume: 9 start-page: 840 year: 2014 ident: 10.1016/S1474-4422(16)30234-4_bib30 article-title: European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage publication-title: Int J Stroke doi: 10.1111/ijs.12309 – volume: 43 start-page: 2923 year: 2012 ident: 10.1016/S1474-4422(16)30234-4_bib32 article-title: Minimally invasive surgery for spontaneous supratentorial intracerebral hemorrhage: a meta-analysis of randomized controlled trials publication-title: Stroke doi: 10.1161/STROKEAHA.112.667535 – volume: 41 start-page: 2108 year: 2010 ident: 10.1016/S1474-4422(16)30234-4_bib18 article-title: Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association publication-title: Stroke doi: 10.1161/STR.0b013e3181ec611b – reference: 20498453 - Stroke. 2010 Jun;41(6):1084-99 – reference: 17938297 - Circulation. 2007 Oct 16;116(16):e391-413 – reference: 23726393 - Lancet. 2013 Aug 3;382(9890):397-408 – reference: 10067918 - J Neurosurg. 1999 Mar;90(3):491-8 – reference: 18480205 - N Engl J Med. 2008 May 15;358(20):2127-37 – reference: 19265046 - Stroke. 2009 May;40(5):1677-82 – reference: 20183466 - J Biopharm Stat. 2009 Nov;19(6):1085-98 – reference: 23843666 - Biometrika. 2012 Jun;99(2):439-456 – reference: 10199544 - Crit Care Med. 1999 Mar;27(3):617-21 – reference: 16926557 - Cerebrovasc Dis. 2006;22(4):294-316 – reference: 20470370 - Health Qual Life Outcomes. 2010 May 14;8:49 – reference: 25156220 - Int J Stroke. 2014 Oct;9(7):840-55 – reference: 25104492 - Lancet Glob Health. 2013 Nov;1(5):e259-81 – reference: 10471432 - Stroke. 1999 Sep;30(9):1833-9 – reference: 10753984 - Stroke. 2000 Apr;31(4):834-40 – reference: 24845086 - Stat Med. 2014 Oct 30;33(24):4170-85 – reference: 23370203 - Stroke. 2013 Mar;44(3):635-41 – reference: 20651276 - Stroke. 2010 Sep;41(9):2108-29 – reference: 22989500 - Stroke. 2012 Nov;43(11):2923-30 – reference: 23391763 - Stroke. 2013 Mar;44(3):627-34 – reference: 22511006 - Stroke. 2012 Jun;43(6):1496-504 – reference: 23713578 - N Engl J Med. 2013 Jun 20;368(25):2355-65 – reference: 18058845 - Stat Med. 2007 Dec 30;26(30):5512-28 – reference: 27751536 - Lancet Neurol. 2016 Nov;15(12):1197-1199 – reference: 19066101 - Acta Neurochir Suppl. 2008;105:147-51 – reference: 25177839 - Cochrane Database Syst Rev. 2014 Sep 01;(9):CD009372 – reference: 21340523 - J Neurol. 2011 Apr;258(4):661-9 – reference: 15680453 - Lancet. 2005 Jan 29-Feb 4;365(9457):387-97 – reference: 16636233 - Neurology. 2006 Apr 25;66(8):1175-81 – reference: 25872751 - Stat Med. 2015 Aug 15;34(18):2602-17 – reference: 10794561 - Minim Invasive Neurosurg. 2000 Mar;43(1):9-17
SSID	ssj0021481
Score	2.6395524
Snippet	Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive catheter... Summary Background Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally... Background Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	1228
SubjectTerms	Aged Blood pressure Cerebral Hemorrhage - drug therapy Cerebral Hemorrhage - mortality Cerebral Hemorrhage - surgery Coma Combined Modality Therapy Female Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - adverse effects Fibrinolytic Agents - pharmacology Follow-Up Studies Hemorrhage Humans Intensive care Laparoscopy Male Middle Aged Minimally Invasive Surgical Procedures Mortality Neurology Outcome Assessment (Health Care) Patients Postoperative Hemorrhage - etiology Pragmatism Stroke Surgery Surgery, Computer-Assisted Thrombectomy - adverse effects Thrombectomy - methods Tissue Plasminogen Activator - administration & dosage Tissue Plasminogen Activator - adverse effects Tissue Plasminogen Activator - pharmacology
Title	Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1474442216302344 https://www.clinicalkey.es/playcontent/1-s2.0-S1474442216302344 https://dx.doi.org/10.1016/S1474-4422(16)30234-4 https://www.ncbi.nlm.nih.gov/pubmed/27751554 https://www.proquest.com/docview/1828223222 https://www.proquest.com/docview/1835454385 https://www.proquest.com/docview/1837328320
Volume	15
WOSCitedRecordID	wos000386315700018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-4465 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0021481 issn: 1474-4422 databaseCode: 7X7 dateStart: 20020501 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-4465 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0021481 issn: 1474-4422 databaseCode: 7RV dateStart: 20020501 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-4465 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0021481 issn: 1474-4422 databaseCode: BENPR dateStart: 20020501 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-4465 dateEnd: 20251008 omitProxy: false ssIdentifier: ssj0021481 issn: 1474-4422 databaseCode: M2M dateStart: 20020501 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEF4ap5Re-m7jNg1b6CGBKJF311q5l9IWhwZqE-I0-Cb2iQOq7Fi2wX-ov7Mz0lq5NEmhYITX0icJz2jmW83sDCEfjdGq57ugvKLTi4RMTKS7NokSr6zv6jipwwWXP-RwmI7HvbPwwq0MaZUbm1gZajs1-I78GHgw-DKMC3yeXUfYNQqjq6GFxhbZxkplokW2v_aHZ-fNlAvIfjXlElJEQjB2s4bneNT8uN9JDrB3Doxu8063sc_KC508_d_7f0aeBP5Jv9QK85w8cMUL8mgQIuwvye-R8m6xpqqw1GF5CWXWdOopliD5pfJ8Ta-KlcKcd1rWK6rpLF-WFKPuM2DiDvbDZzFXxs0xKJ3TicJs3vkELBd1K2Xq4uJ0f3A6ujjtH3yiioLDtFPQOGcPaUiez_E79vaKQE9dfkhnEzw7o1WfkVfk50n_4tv3KPRyiEw3ZYvICg1UTDDPtZaOJaayNNZwD_zN6ERbzoX2ynXinnZKOA_Wj1vuuXPSKMdfk1YxLdwOoUaLhMWpkr3YCwsMlxmYRzkgplwYrtM2ERsZZiYUOsd-G3nWZLSh6DMUfQajSvSZaJOjBjarK33cB0g2CpJtlrGC4c3AF90HlH8DujKYjzLrZCXL4hqNYCDNCAVk2iADQ6qZz79cdHejl9nNdRqlbJMPzW4QN0aNVOGmSzyGA8sWPO3eeQwWfeIsbpM39fPR_IdMSmwjJN7efQPvyGPgokm9zHOXtBbzpXtPHprV4qqc75EteX6J27GstuleeNJhNGCDPzSmVGY
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9NAFB6VgoAL-xIoMEggtVJNnZmJ7SAhhKBVoyYRoqHqbZhVqWScECdB-UMc-Y28560X2nLpAckHO_azo_Fbvue3EfLKGK26vgPMK9rdQMSRCXTHRkHklfUdHUZluOCoHw-HyfFx9_Ma-V3XwmBaZa0TC0VtJwa_ke8ADgZbhnGB99MfAU6NwuhqPUKjZIsDt_oJLlv-rvcJ3u9rxvZ2Rx_3g2qqQGA6CZsHVmgABYJ5rnXsWGQKnreGe0ASRkfaci60V64ddrVTwnmQQ265587FRjkO971CroIeb2MKWfzlqHHwwLUoHDwRi0AIxk4rhnYOmx8329EWTuqBo7Ns4VlYt7B5e7f_t9W6Q25V6Jp-KMXhLllz2T1yfVDlD9wnvw6Vd_MVVZmlDptnKLOiE0-xwcp3laYrepItFWb007ysF6fTdJFTzCmYgp_h4Dxs85kyboYh95SOFeYqz8agl6lbKlO2Tqebg97hqLe79ZYqCnDATkCenN2mVWlAivs4uSwAKXTpNp2O8e6MFlNUHpCvl7JKD8l6NsncY0KNFhELExV3Qy8s4HdmwEt0ALu5MFwnLSJqnpGmauOO00RS2eTrIatJZDUJRwWrSdEibxqyadnH5CKCqGZIWRfpglmRYGkvIoz_RujySjnmsi1zJsOSGonBJUBSoEwaygr_lbjuXx66UcuBPH1OIwQt8rI5Da8bY2Iqc5MFXsPBhxA86Zx7Dba04ixskUelPDZryOIYhySJJ-f_gRfkxv5o0Jf93vDgKbkJqDsqC1o3yPp8tnDPyDWznJ_ks-eFRqHk22UL5R9QgK9k
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VgqpeeEMDBRYJpFaqibO7fgQJIUQbEbWJKqVUvS27612lknFCnATlD_Ej-HXM-NULbbn0gOSDHXvsaD2PbzwvQt4Yo1XXBcC8otP1RBQaTwdJ6IVOJS7QfliGC06PouEwPjvrHq-R33UtDKZV1jqxUNTJxOA38jbgYLBlGBdouyot4ni_93H6w8MJUhhprcdplCxyaFc_wX3LP_T34V2_Zax3cPL5i1dNGPBMELO5lwgNAEEwx7WOLAtNwf-J4Q5QhdGhTjgX2inb8bvaKmEdyCRPuOPWRkZZDve9RW5HIghwesKADRpnD9yMwtkTkfCEYOyieqg9an7c6YS7OLUHji6zi5fh3sL-9e79zyt3n9ytUDf9VIrJA7Jms4dkY1DlFTwiv0bK2fmKqiyhFptqKLOiE0ex8cp3laYrep4tFWb607ysI6fTdJFTzDWYgv9h4Txs85kydoah-JSOFeYwz8agr6ldKlO2VKc7g_7opH-w-54qCjAhmYCc2WSPViUDKe7jRDMPpNOme3Q6xrszWkxXeUy-3sgqPSHr2SSzW4QaLULmxyrq-k4kgOuZAe_RAhznwnAdt4io-Ueaqr07ThlJZZPHh2wnke0kHBVsJ0WLvGvIpmV_k-sIwpo5ZV28C-ZGggW-jjD6G6HNK6WZy47MmfRLaiQGVwFJgTJuKCtcWOK9f3nodi0T8uI5jUC0yOvmNLxujJWpzE4WeA0H30LwOLjyGmx1xZnfIk9L2WzWkEURDk8Sz67-A6_IBsiiPOoPD5-TTQDjYVnnuk3W57OFfUHumOX8PJ-9LJQLJd9uWib_ALY8t_s
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+efficacy+of+minimally+invasive+surgery+plus+alteplase+in+intracerebral+haemorrhage+evacuation+%28MISTIE%29%3A+a+randomised%2C+controlled%2C+open-label%2C+phase+2+trial&rft.jtitle=Lancet+neurology&rft.au=Hanley%2C+Daniel+F%2C+Prof&rft.au=Thompson%2C+Richard+E%2C+PhD&rft.au=Muschelli%2C+John%2C+PhD&rft.au=Rosenblum%2C+Michael%2C+PhD&rft.date=2016-11-01&rft.issn=1474-4422&rft.volume=15&rft.issue=12&rft.spage=1228&rft.epage=1237&rft_id=info:doi/10.1016%2FS1474-4422%2816%2930234-4&rft.externalDBID=ECK1-s2.0-S1474442216302344&rft.externalDocID=1_s2_0_S1474442216302344
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14744422%2FS1474442216X00117%2Fcov150h.gif